FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.
Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas home phototherapy offered lower costs for patients and payers, according to a ...
The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced.
Hosted on MSN
Does psoriasis raise your risk of skin infections?
How Psoriasis Raises the Risk Types of Skin Infections When to See Your Doctor Treatment for Skin Infections Preventing Skin Infections Psoriasis is a skin condition involving the abnormal buildup of ...
Johnson & Johnson (JNJ) stock is in focus as US approves its once-daily pill Icotyde developed with Protagonist Therapeutics ...
AbbVie (ABBV) stock dips as BNP warns J&J’s (JNJ) newly FDA-approved plaque psoriasis pill, Icotyde, may challenge its ...
Everyday Health on MSN
Psoriasis and allergies: What’s the connection?
Learn how psoriasis, allergies, and eczema are connected and how they're different. Get lifestyle tips on managing both.
Psoriasis patients are stigmatized and can later develop debilitating arthritis. July 29, 2011— -- Reality star Kim Kardashian publicly revealed a nasty rash to her dermatologist on a recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results